Arrowhead Research reported $46.63M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 364.27M 12.54M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
Merck USD 2.86B 25M Sep/2026
Moderna USD 282M 66M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.08B 163M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
TG Therapeutics USD 88.22M 25.89M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026